Home・Stock List・Insmed

Insmed

Closed

SectorHealthcare

98.72 0.46

Buy Sell

Overview

Share price change

24h

Current

Min

96.22

Max

99.38

Key metrics
By Trading Economics
Income	165M -164M
Sales	42M 306M
EPS	-0.76
Profit margin	-53.458
Employees	1,664
EBITDA	164M -136M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+100.98% upside

Dividends
By Acuity
Next Earnings	6 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-7.5B 23B
Previous open	98.26
Previous close	98.72

News Sentiment

By Acuity

43%

57%

135 / 340 Healthcare

Insmed Chart

Past performance is not a reliable indicator of future results.

Related News

3 Aug 2026, 19:16 UTC

Insmed Inc shares are lower today, marking the seventh consecutive session of declines. No specific company news was identified to explain the movement.

31 Jul 2026, 20:06 UTC

Insmed Inc. shares are lower, continuing a seven-session decline amid rising Treasury yields and crude oil prices, with no specific company news identified.

30 Jul 2026, 21:16 UTC

Insmed Inc shares are higher in after-market trading, recovering from earlier losses. The stock rose to a high since Thursday's close.

28 Jul 2026, 19:26 UTC

Insmed Inc shares are lower today, with no specific news identified. Broader market sentiment is bearish, influenced by declines in Asian markets.

27 Jul 2026, 23:41 UTC

Insmed Inc's shares are higher in after-market hours, rebounding from a lower regular session. No specific news was identified for this price movement.

24 Jul 2026, 23:46 UTC

Insmed Inc shares are lower in after-market hours, continuing recent trends. The stock remains near the lower end of its one-month trading range.

22 Jul 2026, 19:11 UTC

Social Media

Insmed shares are lower despite Cantor Fitzgerald's "Overweight" rating and $235 price target, following positive updates on inhalation powder TPIP.

21 Jul 2026, 17:41 UTC

Social Media

News

BMO Capital initiated coverage on Insmed Inc with an Outperform rating and a $192 price target, contributing to the stock's upward movement.

20 Jul 2026, 19:16 UTC

News

Social Media

Insmed Inc's shares are lower today amid declines in the Biotechnology sector. Social media highlights positive sentiment around TPIP data and its strong pipeline.

Peer Comparison

Price change

Insmed Forecast

Price Target

By TipRanks

100.98% upside

12 Months Forecast

Average 198.17 USD 100.98%

High 243 USD

Low 160 USD

Based on 20 Wall Street analysts offering 12 month price targets forInsmed - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

20 ratings

Buy

Hold

Sell

Based on 20 analysts giving stock ratings to Insmed - Dist in the past 3 months.

Sentiment

By Acuity

135 / 340 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Insmed

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.